Cabergoline
Overview
Cabergoline is a long-acting dopamine receptor agonist used primarily in the treatment of disorders associated with hyperprolactinemia, including prolactin-secreting adenomas. It has been found effective in reducing prolactin levels and tumor size.
API suppliers (7)
Suppliers of Cabergoline evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 3 of 7 suppliers.
1 of 7 holds a GMP certificate on record in the EU or UK registers
- TAPI NL BVNetherlands1 active DMF
- CF PHARMA LTD1 active DMF
- Apotex Pharmachem India Pvt. Ltd.India
- MYLAN LABORATORIES LTD GMP on record
- Pfizer LtdUnited Kingdom
- Gedeon Richter Usa
- IVAX CR
EU CEP holders (4)
Companies holding a valid EU Certificate of Suitability (CEP) for Cabergoline, from the EDQM certification database. A CEP holder is a documented EU-market source of the substance — not necessarily the manufacturer — and these are not yet profiled in our directory.
Therapeutic areas
Do you supply Cabergoline? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.